All Stories

  1. Progression-survival dissociation in connective tissue disease (CTD)-associated interstitial lung disease (ILD): CTD-ILD versus non-CTD ILD in real-world practice
  2. KL-6 as a Biomarker for Adult Patients with Cystic Fibrosis and the Impact of MUC1 Genotype
  3. The burden of autoimmune pulmonary alveolar proteinosis: a systematic review
  4. Sex-specific phenotypes and outcomes in non‑IPF interstitial lung disease: results from the INSIGHTS‑ILD registry
  5. Challenges in diagnosis of sarcoidosis
  6. Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement
  7. Sarcoidosis: A State-Of-The-Art Review
  8. Design of a Phase II randomised, double-blind, placebo-controlled, dose-finding trial of BI 1819479 in patients with idiopathic pulmonary fibrosis
  9. Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
  10. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
  11. Summary for clinicians: ERS guidelines on pulmonary alveolar proteinosis
  12. Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry
  13. The role of heat shock protein 90 in idiopathic pulmonary fibrosis: state of the art
  14. European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
  15. Pathogenesis-driven treatment of primary pulmonary alveolar proteinosis
  16. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
  17. Kidney manifestations of sarcoidosis
  18. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival
  19. Will inhalational GM-CSF replace whole lung lavage as a treatment for autoimmune pulmonary alveolar proteinosis? Many pole positions, not yet the final winner
  20. Pulmonale Alveolarproteinose (PAP)
  21. Pulmonale alveoläre Mikrolithiasis (PAM)
  22. Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
  23. Serum KL-6 as a Candidate Predictor of Outcome in Patients with SARS-CoV-2 Pneumonia
  24. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
  25. Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
  26. MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis
  27. European Respiratory Society Statement on Familial Pulmonary Fibrosis
  28. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe
  29. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective
  30. COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study
  31. Genetic testing in interstitial lung disease: An international survey
  32. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
  33. Targeted therapy for pulmonary alveolar proteinosis: the time is now
  34. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
  35. Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
  36. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden
  37. Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study
  38. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  39. Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting
  40. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  41. S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis
  42. Potential Clinical Utility of MUC5B und TOLLIP Single Nucleotide Polymorphisms (SNPs) in the Management of Patients with IPF
  43. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
  44. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
  45. Ganzlungenlavage bei pulmonaler Alveolarproteinose – Schritt für Schritt
  46. Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
  47. Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment
  48. When the Game Changes
  49. Hypersensitivity pneumonitis
  50. The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value?
  51. Looking into the future of sarcoidosis: what is next for treatment?
  52. Shedding light on developmental drugs for idiopathic pulmonary fibrosis
  53. Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19
  54. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis
  55. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review
  56. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis
  57. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
  58. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  59. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
  60. Genotype in MUC5B-Promoter Polymorphism and Chronic Lung Allograft Dysfunction (CLAD) in a German Cohort: Preliminary Results
  61. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  62. Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
  63. Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease
  64. Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study
  65. Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
  66. Quantitative Lipidomics in Pulmonary Alveolar Proteinosis
  67. Shaping the future of an ultra-rare disease
  68. Editorial introductions
  69. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
  70. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
  71. Correction to: The Burden of Sarcoidosis Symptoms from a Patient Perspective
  72. Pulmonary alveolar proteinosis
  73. The Burden of Sarcoidosis Symptoms from a Patient Perspective
  74. Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients
  75. Erratum zu: Differenzialdiagnose interstitieller Lungenerkrankungen – „Interstitial pneumonia with autoimmune features“ (IPAF)
  76. Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia
  77. Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study
  78. Differenzialdiagnose interstitieller Lungenerkrankungen
  79. Die „Rheumalunge“ in der Computertomographie: radiologische Manifestationen der rheumatoiden Arthritis
  80. The Management of Patients With Idiopathic Pulmonary Fibrosis
  81. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
  82. Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen – klinische Sektion der DGP
  83. Patients with IPF and lung cancer: diagnosis and management
  84. German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
  85. Phenotypes of organ involvement in sarcoidosis
  86. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies
  87. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis
  88. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
  89. Serum YKL-40 in workers at an indium-tin oxide production facility - Reply
  90. Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity
  91. Therapeutic targets in idiopathic pulmonary fibrosis
  92. Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
  93. Differential diagnosis of granulomatous lung disease: clues and pitfalls
  94. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis
  95. S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
  96. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis
  97. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
  98. Coagulation factor XII regulates inflammatory responses in human lungs
  99. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis
  100. Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis
  101. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
  102. Deutschsprachige Validierung des „Kingʼs Brief Interstitial Lung Disease (K-BILD)“ Lebensqualitätsfragebogens für interstitielle Lungenerkrankungen
  103. New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis
  104. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures
  105. Epidemiologie und klinisches Erscheinungsbild der Sarkoidose
  106. A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis
  107. European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity
  108. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis
  109. How to handle IPF – the new Portuguese consensus document
  110. An Important Step Forward, but Still a Way to Go
  111. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
  112. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
  113. Pulmonary alveolar proteinosis in a cat
  114. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
  115. Pulmonale Alveolarproteinose
  116. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
  117. New guideline on treatment of idiopathic pulmonary fibrosis
  118. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders
  119. Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)
  120. Facts and promises on lung biomarkers in interstitial lung diseases
  121. Diagnosis of Sarcoidosis
  122. Update on therapeutic management of idiopathic pulmonary fibrosis
  123. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis
  124. MUC5Bpromoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis
  125. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
  126. Alveolar and intraparenchymal proteasome in sarcoidosis
  127. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?
  128. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis
  129. Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
  130. Interstitial lung disease
  131. Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPDgene polymorphisms
  132. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases
  133. The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease
  134. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia
  135. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  136. Sarkoidose
  137. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  138. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
  139. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels
  140. Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases
  141. Hypersensitivity Pneumonitis
  142. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis
  143. Chronic Hypersensitivity Pneumonitis
  144. KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome
  145. Self-reported asthma and respiratory symptoms among Italian amateur athletes
  146. Whole-Lung Lavage: A Successful Treatment for Restoring Acinar Ventilation Distribution in Primary Acquired Pulmonary Alveolar Proteinosis
  147. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation
  148. Pulmonary alveolar proteinosis: New insights from a single-center cohort of 70 patients
  149. Therapie der Lungenfibrose
  150. Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET
  151. A female soccer player with recurrent haemoptysis and iron deficiency anaemia: idiopathic pulmonary haemosiderosis (IPH)--case report and literature review
  152. Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease
  153. To BAL or Not to BAL: Is This a Problem in Diagnosing IPF?
  154. Die bronchoalveoläre Lavage aus klinischer Sicht
  155. Significance of Bronchoalveolar Lavage for the Diagnosis of Idiopathic Pulmonary Fibrosis
  156. Acid reflux into the oesophagus does not influence exercise-induced airway narrowing in bronchial asthma
  157. Bronchoalveolar Lavage in Other Interstitial Lung Diseases
  158. Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux
  159. Biomarkers